AUS Peptide Supply

The early access event

Black
Friday.

20%OFF

Storewide. Starting now.

Early Black Friday

Your favourites.
An earlier saving.

Get 20% off all APS products. Sale prices are already applied, so you can get straight to shopping.

  • No discount code needed
  • Stacks with volume savings
  • Save up to 32% on eligible quantities
Shop the sale

APS products only. Partner offers excluded. Shipping and payment fees calculated at checkout.

The Research Journal.Peptide science, in perspective.
Evidence dossierPublished Updated Version 1.0

Sermorelin Acetate research guide

Acetate salt of amidated 29-residue GHRH fragment

What the Sermorelin Acetate name specifies, how GHRH(1-29)-amide differs from related analogues, and what a historical clinical study can and cannot establish.

AUS Peptide Supply editorial team
GHRH(1-29)-amideGRF(1-29)-NH2

01 · Identity

What the name identifies

Sermorelin is the amidated 29-residue amino-terminal fragment of human growth-hormone-releasing hormone. Sermorelin Acetate names its acetate salt form. The peptide sequence, salt designation and quantitative reporting basis should be recorded separately rather than compressed into a generic GHRH label.

02 · Evidence position

What the literature can support

The selected human study was a historical multicentre open-label investigation in children with growth-hormone deficiency. It is relevant to that studied product and population, not evidence of general anti-ageing or body-composition effects. Its design does not supply a modern batch identity or purity certificate.

03 · Study-level map

Evidence and its limits

Analytical identity

What do the peptide and acetate names specify?

The PubChem reference identifies the amidated GHRH(1-29) peptide. The catalogue label separately specifies an acetate material designation.

Limit: A reference identity does not settle the counter-ion content, moisture or quantitative assay basis of a supplied sample.

Human open-label

What population and design appear in the historical trial?

The 1996 Geref study enrolled 110 previously untreated prepubertal children with growth-hormone deficiency in a multicentre open-label study lasting up to one year. Eighty-six were included in the efficacy analysis.

Limit: It was not a placebo-controlled demonstration of broad benefits in healthy adults. The study product does not verify this catalogue material.

04 · Analytical context

Questions a batch record should answer

  1. 01Do sequence and terminal amidation match the sermorelin reference identity?
  2. 02Is the acetate form and its reporting basis stated rather than assumed from a name?
  3. 03Does the measured amount refer to peptide content, total material or another explicitly defined quantity?

05 · Boundary conditions

What this record does not establish

  • A common GHRH-related pathway does not make Sermorelin, CJC-1295 and Tesamorelin identical.
  • No peptide-only mass is inferred from an unqualified vial quantity label.
  • No verified APS CoA is available for the associated product at publication.

Sources checked

  1. 1.
    Sermorelin — PubChem CID 16132413

    NIH PubChem · 2026 · Chemical database

  2. 2.

Continue through the topic